RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D018276:Carcinoma, Medullary / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D018813:Multiple Endocrine Neoplasia Type 2a / Q000378:metabolism*; D018814:Multiple Endocrine Neoplasia Type 2b / Q000378:metabolism*; D015513:Oncogene Proteins / Q000187:drug effects* / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D051096:Proto-Oncogene Proteins c-ret; D011720:Pyrazoles / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D020794:Receptor Protein-Tyrosine Kinases / Q000187:drug effects* / Q000378:metabolism*; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000378:metabolism
C108123:4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine; D000970:Antineoplastic Agents; D015513:Oncogene Proteins; D011720:Pyrazoles; D011743:Pyrimidines; D051096:Proto-Oncogene Proteins c-ret; C099282:RET protein, human; D020794:Receptor Protein-Tyrosine Kinases